Allogenic Stem Cell Therapy in Patients With Acute Burn
Status:
Unknown status
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
Burn trauma,especially extensive ones, remains a life-threatening local and general
inflammatory condition destroying the skin and underlying tissues, and resulting in serious
sequelae. Remarkable progress has been achieved during last 30 years，stem cell therapy plays
an important role in this progress. Human umbilical cord mesenchymal stem cells (hUCMSCs) and
human cord blood mononuclear cells (hCBMNCs) have been shown to have the ability to modulate
the immune response and enhance angiogenesis, suggesting the novel and promising therapeutic
strategy for burn. In this study, the safety and efficacy of hUCMSCs and hCBMNCs
transplantation will be evaluated in patients with acute burn.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Shenzhen Beike Bio-Technology Co., Ltd.
Collaborator:
The Second Affiliated Hospital of Kunming Medical University